JENSCARE-B's Ken-Valve Transcatheter Aortic Valve System Receives Approval from Hong Kong Department of Health

Stock News
Jun 22

The company has announced that its transcatheter aortic valve system, Ken-Valve, has recently received approval from the Department of Health of the Hong Kong Special Administrative Region.

The firm is actively advancing the commercialization of this product within the Hong Kong market.

Owing to the product's distinct advantages, ongoing therapy promotion efforts, and extensive commercialization experience, Ken-Valve has already gained broad market recognition.

This latest approval from the Hong Kong Department of Health further validates the product's potential in treating aortic regurgitation, including cases with concurrent stenosis.

The company remains committed to fully accelerating the global commercialization process for Ken-Valve to further realize its long-term strategic objectives.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10